Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galinpepimut S - SELLAS Life Sciences Group

Drug Profile

Galinpepimut S - SELLAS Life Sciences Group

Alternative Names: FPI-01; GPS-Memorial-Sloan-Kettering-Cancer-Center/Sellas-Life-Sciences-Group; SLS-001; WT-1 analog peptide vaccine-Memorial-Sloan-Kettering; WT-1-analogue-peptide-vaccine-Memorial-Sloan-Kettering; WT1 cancer vaccine - SELLAS Life Sciences; WT1 peptide vaccine - Memorial Sloan Kettering; WT1 vaccine - Memorial Sloan Kettering; WT1-cancer-vaccine-Memorial-Sloan-Kettering; WT1-peptide-vaccine-Sellas-Life-Sciences-Group; ZELTHERVA

Latest Information Update: 02 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Bristol-Myers Squibb; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme Corp.; Sellas Life Sciences Group
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Acute myeloid leukaemia; Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Cancer; Mesothelioma; Multiple myeloma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 12 Nov 2021 SELLAS Life Sciences receives approval to commence the REGAL study in Hungary and Taiwan
  • 12 Nov 2021 SELLAS Life Sciences plans a phase II/III GPS study in acute myeloid leukemia post-transplant patients
  • 30 Jun 2021 Efficacy and Immunogenicity data from a phase I/II trial in Ovarian cancer released by Sellas Life Sciences Group
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top